Median Technologies to participate in the 2023 ASCO Annual Meeting, June 2-6, 2023, McCormick Place, Chicago, IL, USA
01 Junho 2023 - 12:45PM
Business Wire
Regulatory News:
Median Technologies (ALMDT) announced today that the Company
will be participating in the 2023 American Society of Clinical
Oncology (ASCO) Annual Meeting taking place from June 2 to 6,
McCormick Place, Chicago, IL, USA. The Median team, with iCRO and
iBiopsy® representatives as well as the Company clinical team will
be pleased to welcome the ASCO participants at booth #2050, South
Building, Hall A, McCormick place, from June 3 to 5 (exhibition
dates), from 9:00 am to 5:00 pm.
Two Median Technologies’ abstracts have been selected for online
publication:
Abstract #e20599: CT Based
Radiomics Signature for Phenotyping Histopathological Subtype in
Patients With Non-Small Cell Lung Cancer The study in this
abstract aimed to use a CT-based radiomics model to predict the
histopathological subtype of non-small cell lung cancer (NSCLC)
patients. The study included 678 patients, with 531 used for
training and 147 for testing. The robust radiomics features
extracted from the CT scans were used to train a support vector
machine (SVM) classifier, which achieved an accuracy of 0.80 on the
training set and 0.77 on the test set. The study showed that
CT-based radiomics can accurately predict the histopathology
subtype of NSCLC patients, offering a less invasive and more
cost-effective alternative to traditional tissue analysis
methods.
Abstract #e20515:
Multicenter Evaluation of AI-Based CT Radiomics for EGFR
Mutation Prediction in NSCLC This abstract discusses using CT
image-based radiomics model as a non-invasive solution to predict
EGFR mutation status in NSCLC. The study collected CT images from
multiple centers and open-source databases to investigate the
performance of the model. The model achieved promising results with
an AUC of 0.83 on cross-validation and an AUC of 0.76 on the test
set. The authors conclude that AI-powered medical image analysis
has the potential to serve as predictive biomarkers for guiding
targeted therapies in the future.
The Median’s Imaging Lab team will be at booth #2050, to discuss
abstract results. The team will also host two sessions on June 3rd
and June 4th, at 4:15 pm CDT at booth, to highlight how Imaging Lab
is shaping the future of clinical development with the latest in
AI-powered imaging intelligence.
The ASCO Annual Meeting is the world’s premier oncology
conference, organized by the American Society of Clinical Oncology,
the largest oncology society in the world. Each year, the ASCO
conference brings together more than 35,000 oncologists from all
around the globe, and is attended by all medical, educational and
industrial stakeholders involved in the field of oncology
worldwide. More about the ASCO Annual Meeting:
https://am.asco.org/
About Median Technologies: Median Technologies provides
innovative imaging solutions and services to advance healthcare for
everyone. We harness the power of medical images by using the most
advanced Artificial Intelligence technologies, to increase the
accuracy of diagnosis and treatment of many cancers and other
metabolic diseases at their earliest stages and provide insights
into novel therapies for patients. Our iCRO solutions for medical
image analysis and management in oncology trials and iBiopsy®, our
AI-powered imaging platform for the development of software as
medical devices (SaMD) help biopharmaceutical companies and
clinicians to bring new treatments and diagnose patients earlier
and more accurately. This is how we are helping to create a
healthier world.
Founded in 2002, based in Sophia-Antipolis, France, with a
subsidiary in the US and another one in Shanghai, Median has
received the label “Innovative company” by the BPI and is listed on
Euronext Growth market (Paris). FR0011049824– ticker: ALMDT. Median
is eligible for the French SME equity savings plan scheme
(PEA-PME). For more information: www.mediantechnologies.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230601005030/en/
Median Technologies Emmanuelle Leygues Head of Corporate
Marketing & Financial Communications +33 6 10 93 58 88
emmanuelle.leygues@mediantechnologies.com
Press - ALIZE RP Caroline Carmagnol +33 6 64
18 99 59 median@alizerp.com
Investors - ACTIFIN Ghislaine Gasparetto +33 6 21 10 49
24 ggasparetto@actifin.fr
Median Technologies (EU:ALMDT)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Median Technologies (EU:ALMDT)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024